Transtek(SZ:300562)2025-01-21 08:58Financial Performance - The estimated net profit attributable to shareholders for 2024 is expected to be RMB 60 million, representing a growth of 74.58% compared to the previous year's profit of RMB 34.37 million[4]. - The net profit after deducting non-recurring gains and losses is projected to be RMB 56 million, reflecting a significant increase of 148.46% from RMB 22.54 million in the same period last year[4]. - The impact of non-recurring gains and losses on the net profit is estimated to be RMB 3.8 million[8]. - The performance forecast indicates a positive outlook for the company's profitability in 2024[6]. Strategic Focus - The company aims to enhance operational efficiency through improved accounts receivable and inventory management, leading to better turnover rates[7]. - The company is focusing on the digital chronic disease management sector and expanding its product matrix to improve competitiveness in home medical devices and services[7]. - The company plans to optimize its customer structure by increasing the proportion of high-quality customers to enhance overall gross profit[7]. - The company is committed to implementing its medium to long-term strategic planning alongside its annual operational plans[7]. Financial Reporting - The financial data presented in the earnings forecast has not been audited by an external accounting firm[5]. - The specific financial data for the 2024 annual performance will be disclosed in the company's annual report[9].